Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Loxapine succinate
Drug ID BADD_D01327
Description An antipsychotic agent used in schizophrenia. [PubChem]
Indications and Usage For the management of the manifestations of psychotic disorders such as schizophrenia
Marketing Status approved
ATC Code N05AH01
DrugBank ID DB00408
KEGG ID D00794
MeSH ID D008152
PubChem ID 71399
TTD Drug ID D0U5OE
NDC Product Code 64330-112; 53296-0017
UNII X59SG0MRYU
Synonyms Loxapine | 2-Chloro-11-(4-methyl-1-piperazinyl)-dibenz(b,f)(1,4)oxazepine | Oxilapine | Cloxazepine | Loxapine Hydrochloride | Hydrochloride, Loxapine | Loxitane | Loxapine Succinate | Succinate, Loxapine | Loxapinsuccinate | Loxipine Succinate | Loxipine Maleate | Maleate, Loxipine | CL-71,563 | CL 71,563 | CL71,563 | Loxapine Monohydrochloride
Chemical Information
Molecular Formula C22H24ClN3O5
CAS Registry Number 27833-64-3
SMILES CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Leukopenia01.02.02.001--Not Available
Menstruation irregular21.01.01.005; 05.05.01.008--
Muscle rigidity17.05.02.005; 15.05.04.001--Not Available
Muscle spasms15.05.03.004--
Muscle twitching15.05.03.005--Not Available
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Neuroleptic malignant syndrome17.05.02.003; 15.05.04.015; 12.03.01.003; 08.05.01.005--Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Paraesthesia17.02.06.005; 23.03.03.094--
Polydipsia14.05.02.001; 05.03.03.002--Not Available
Protrusion tongue17.02.05.037; 07.14.02.002--Not Available
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Salivary hypersecretion07.06.01.009--Not Available
Seborrhoea23.02.07.001--Not Available
Seizure17.12.03.001--
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Tachycardia02.03.02.007--Not Available
Tardive dyskinesia17.01.02.012--Not Available
Tension19.06.02.005--Not Available
Throat tightness22.12.03.031; 19.01.02.005--Not Available
Thrombocytopenia01.08.01.002--Not Available
Tremor17.01.06.002--
Urinary retention20.02.02.011--
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages